Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 11:30 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1705–1728 of 16,130 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Skin Disorder Clear all

Conditions: Metastatic Breast Cancer
Interventions: Fulvestrant, Tamoxifen, Palbociclib; Drug
Lead sponsor: Shannon Puhalla; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Dermatitis, Allergic Contact
Interventions: Patch Test; Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 2
States / cities: Mineola, New York • Cincinnati, Ohio

Conditions: Cutaneous Lupus Erythematosus (CLE)
Interventions: Not listed
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2030
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Dallas, Texas

Conditions: Staphylococcus Aureus Skin Infection
Interventions: S. aureus; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 2 Years to 65 Years
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Systemic Lupus Erythematosus
Interventions: Premarin and Provera; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 85 Years · Female only
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2002
U.S. locations: 16
States / cities: Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 12 more

Conditions: Onychomycosis of Toenail, Onychomycosis
Interventions: plasma treatment; Device
Lead sponsor: DeviceFarm, Inc.; Industry
Eligibility: 21 Years to 75 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Breast Cancer, Colon Cancer, Bladder Cancer
Interventions: Glycosylated Recombinant Human Interleukin-7, Diphtheria/Tetanus Vaccine, Polio Vaccine, Pneumococcal Vaccine, Hepatitis A Vaccine, Hepatitis B Vaccine; Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 60 Years to 100 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 2
States / cities: Bethesda, Maryland • New York, New York

Conditions: Hair Loss, Hair Loss/Baldness, Female Pattern Baldness, Androgenetic Alopecia
Interventions: HairDx Sample Collection Kit; Device
Lead sponsor: Applied Biology, Inc.; Industry
Eligibility: 18 Years and older · Female only
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Irvine, California

Conditions: Herpes Simplex
Interventions: Non-adjuvanted HSV formulation 1, Non-adjuvanted HSV formulation 2, Non-adjuvanted HSV formulation 3, HSV formulation 1 with adjuvant 1, HSV formulation 2 with adjuvant 1, HSV formulation 3 with adjuvant 1, HSV formulation 1 with adjuvant 2, HSV formulation 2 with adjuvant 2, HSV formulation 3 with adjuvant 2, Placebo, HSVTI_F1, HSVTI_F2; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 505 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 6
States / cities: Phoenix, Arizona • Wichita, Kansas • Kansas City, Missouri + 3 more

Conditions: Breast Cancer
Interventions: Communication Tool; Other
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 75 Years and older · Female only
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Actinic Keratosis
Interventions: LEO 43204 gel 0.018%, LEO 43204 gel 0.1%, LEO 43204 gel 0.037%; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Pflugerville, Texas

Conditions: Breast Cancer
Interventions: vepdegestrant, Samuraciclib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 19
States / cities: Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 9 more

Conditions: Melanoma
Interventions: Nivolumab, Placebo; Biological · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 12 Years and older
Enrollment: 790 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 32
States / cities: Birmingham, Alabama • Tucson, Arizona • Springdale, Arkansas + 24 more

Conditions: Breast Cancer
Interventions: weight loss counseling; Behavioral
Lead sponsor: Wayne State University; Other
Eligibility: 18 Years to 71 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Metastatic Breast Cancer, End of Life
Interventions: Clinician Qualitative Interview; Behavioral
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: Not listed
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Breast Cancer, Gastric Cancer, Ovarian Cancer
Interventions: HER-2/neu intracellular domain protein, therapeutic autologous dendritic cells; Biological
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2002
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Herpes Simplex, HIV Infections
Interventions: Foscarnet sodium; Drug
Lead sponsor: Astra USA; Industry
Eligibility: 12 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Tinea Pedis
Interventions: W0027, Placebo; Drug
Lead sponsor: Stiefel, a GSK Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 4
States / cities: Louisville, Kentucky • Warren, Michigan • Albuquerque, New Mexico + 1 more

Conditions: Aphthous Stomatitis, Burning Mouth Syndrome, Lichen Planus, Mouth Disease, Temporomandibular Joint Disorder
Interventions: Electrocardiogram, Biopsies, Diagnostic imaging; Procedure
Lead sponsor: National Institute of Dental and Craniofacial Research (NIDCR); NIH
Eligibility: Not listed
Enrollment: 999 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Lupus Nephritis
Interventions: Obinutuzumab, Placebo, Mycophenolate Mofetil, Acetaminophen/paracetamol, Diphenhydramine hydrochloride (HCl), Methylprednisolone, Prednisone; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 11
States / cities: Loma Linda, California • San Francisco, California • Aurora, Colorado + 8 more

Conditions: Psoriasis, Plaque-type
Interventions: Thalidomide oral; Drug
Lead sponsor: Wake Forest University; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Chronic Inducible Urticaria
Interventions: Oral EP262; Drug
Lead sponsor: Escient Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 7
States / cities: Tampa, Florida • Boise, Idaho • Owensboro, Kentucky + 4 more

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2032
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Lax Skin
Interventions: Sofwave; Device
Lead sponsor: Sofwave Medical LTD; Industry
Eligibility: 35 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: La Mesa, California • Durham, North Carolina

Search by objective public record fields.

Treatment of Metastatic Breast Cancer With Fulvestrant Plus Palbociclib or Tamoxifen Plus Palbociclib

Cutaneous and Systemic Reactions to Metal Implants

Prevalence and Clinical Severity of Cutaneous Lupus Erythematosus

Human Immunity Against Staphylococcus Aureus Skin Infection

Safety of Estrogens in Lupus: Hormone Replacement Therapy

Early Feasibility Study to Evaluate the Efficacy of the RenewalNail™ Plasma Treatment System in Patients With Onychomycosis (Fungal Nail)

Improving the Immune System With Human IL-7 Vaccine in Older Subjects Who Have Had Chemotherapy

HairDx Analytical Validation Study

A Study on the Reactogenicity, Safety, Immune Response, and Efficacy of a Targeted Immunotherapy Against HSV in Healthy Participants Aged 18-40 Years or in Participants Aged 18-60 Years With Recurrent Genital Herpes

Individualizing Surveillance Mammography for Older Breast Cancer Survivors

Pharmacokinetics of LEO 43204 Gel in Actinic Keratosis Administered Under Maximal Use Conditions

TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C)

Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma

Peer Counseling for Weight Loss

Evaluation of the Acceptability, Appropriateness, and Feasibility/Usability of a Metastatic Breast-cancer Specific Prognostic Calculator Among Clinicians

Biological Therapy in Treating Patients With Advanced Cancer

An Open, Multicenter Study of Foscarnet Treatment of Acyclovir-Resistant Herpes Simplex Virus in Patients With the Acquired Immunodeficiency Syndrome and Other Immunodeficiencies

A Study to Evaluate Efficacy and Safety of Three W0027 Regimens in the Treatment of Moccasin Type Tinea Pedis (MTTP)

Evaluation and Treatment of Oral Soft Tissue Diseases

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants

Thalidomide in the Treatment of Chronic Plaque Psoriasis.

Phase 1b, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Chronic Inducible Urticaria

Intra-Operative Radiation Registry

Treatment to Lift Facial Lax Skin and Improve Facial Wrinkles Using Precise and Lift Applicators